Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3073–3096 of 85,985 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Neuroblastoma
Interventions: Topotecan, Temozolomide, Ribociclib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • New Hyde Park, New York • Memphis, Tennessee

Conditions: Advanced Cancers, DLBCL, Lymphoma
Interventions: IONIS-STAT3Rx; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 9
States / cities: Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut + 6 more

Conditions: Pain, Postoperative
Interventions: fentanyl; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Unhealthy Diet
Interventions: Physician communication; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cancer, Healthy
Interventions: Cooked parsnips with parsley; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 7
States / cities: Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more

Conditions: Healthy, Opioid-induced Constipation
Interventions: TD-1211, Placebo; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: Pasadena, California • San Antonio, Texas • Salt Lake City, Utah

Conditions: Myeloid Leukemia
Interventions: AVE9633; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Nontherapeutic
Interventions: e-cigarette, cigarette substitute; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 520 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Richmond, Virginia

Conditions: Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions: Xylitol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pseudoaphakia
Interventions: Ophthalmic Biometer; Device
Lead sponsor: Haag Streit USA; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Interventions: Codrituzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Brain Injuries
Interventions: Advocacy training curriculum, Self-directed; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Urbandale, Iowa • Minneapolis, Minnesota • Pewaukee, Wisconsin

Conditions: Overweight, Obesity
Interventions: High sugar versus low sugar meals; Other
Lead sponsor: University of Southern California; Other
Eligibility: 14 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vascular Disease, Coronary Artery Disease Risk Factors Multiple
Interventions: PZ-128; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Micropatch; Device
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Fertility Issues, Disclosure, Parenting
Interventions: TELL Tool Intervention, eBook Attention Control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dietary Modification
Interventions: Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin; Dietary Supplement · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions: Switch to E/C/FTC/TAF daily; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Hyperglycemia
Interventions: Closed-loop blood glucose control; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Major Depressive Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Alprazolam, control group; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Onychomycosis
Interventions: light therapy; Device
Lead sponsor: Nomir Medical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Southborough, Massachusetts

Search by objective public record fields.

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants

Reduction of Excessive Calories From Beverages in Children

Development of a Biomarker for Dietary Furanocoumarins

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

Time Study for Biometry Measurements With the Lenstar and IntraOcularLens (IOL) Master 500

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Behavioral Trial Studying Programmed Training to Improve Advocacy Skills for Individuals With Traumatic Brain Injury

Food, Adolescence, Mood, and Exercise

Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors

Micropore Closure Kinetics at Various Body Sites

Feasibility Trial of the TELL Tool Intervention

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

Inpatient Closed-loop Glucose Control

Remibrutinib in Real-world Clinical Practice

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

Using Light Therapy to Treat Toe Nail Fungus